Gemcitabine and pemetrexed disodium combinations in vitro and in vivo

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Pemetrexed disodium is broadly active in a wide variety of solid tumours, including non-small cell lung, breast, bladder, head and neck and ovarian cancers. Gemcitabine is a broadly active pyrimidine nucleoside antimetabolite, which is approved for the treatment of pancreatic and non-small cell lung cancers. Three preclinical studies have been reported that show cytotoxic synergy between gemcitabine and pemetrexed. Clinical activity with this combination has been observed in a phase I study, with partial responses in three of five patients previously treated for non-small cell lung cancer. An international phase II study of this combination in non-small cell lung cancer is ongoing.

Original languageEnglish (US)
Pages (from-to)103-105
Number of pages3
JournalLung Cancer
Volume34
Issue numberSUPPL. 4
DOIs
StatePublished - Jan 1 2001

Keywords

  • Antifolate
  • Gemcitabine
  • Pemetrexed disodium
  • Thymidylate synthase

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint Dive into the research topics of 'Gemcitabine and pemetrexed disodium combinations in vitro and in vivo'. Together they form a unique fingerprint.

Cite this